|  |
| --- |
| Supplementary Table 3. Quality Assessment NOS |
|  | **Selection (max. 4 starts)** | **Comparatibility (max. 2 starts)** | **Outcome** **(max. 2 starts)** | **NOS** |
| **Author/year**  | **Represen****tativeness** | **Sample size** | **Non-responders** | **Ascertainment of the exposure****(absent/exclusion)** | **Control age/****gender** | **Control any other factor** | **Assessment** | **Statistical****test** | **Risk bias****score** |
| Alkhames et al., (2021)36 | **\*** | **\*** | **\*** |  | **\*** | **\*** | **\*** | **\*** | **7** |
| Chow et al., (2020)24 | **\*** | **\*** |  |  | **\*** | **\*** | **\*** | **\*** | **6** |
| Farsi et al., (2020)37 | **\*** | **\*** | **\*** |  | **\*** | **\*** | **\*** | **\*** | **7** |
| Kannampallil et al., (2020)24 | **\*** | **\*** |  |  | **\*** | **\*** | **\*** | **\*** | **6** |
| Khalafallah et al., (2020)25 | **\*** | **\*** |  |  | **\*** | **\*** | **\*** | **\*** | **6** |
| Kaplan et al., (2021)26 | **\*** | **\*** |  | **\*** | **\*** | **\*** | **\*** | **\*** | **7** |
| Mendoca et al., (2021)42 |  |  |  |  |  | **\*** | **\*** |  | **2** |
| Mion et al., 202130 | **\*** |  |  |  | **\*** | **\*** | **\*** | **\*** | **5** |
| Treluyer & Tourneux, (2020)31 | **\*** | **\*** |  |  | **\*** | **\*** | **\*** | **\*** | **6** |
| Cravero et al., (2000)44 |  | **\*** |  |  | **\*** | **\*** | **\*** | **\*** | **5** |
| Khooduruth et al., (2021)39 | **\*** | **\*** |  |  | **\*** | **\*** | **\*** | **\*** | **6** |
| Aebischer et al., (2020)32 |  | **\*** |  |  | **\*** | **\*** | **\*** | **\*** | **5** |
| Al-Humadi et al., (2021)45 | **\*** | **\*** |  | **\*** | **\*** | **\*** | **\*** | **\*** | **7** |
| Civantos et al., (2020)27 |  **\*** | **\*** |  |  | **\*** | **\*** | **\*** | **\*** | **6** |
| Coleman et al., (2021)28 |  **\*** | **\*** |  |  | **\*** | **\*** | **\*** | **\*** | **6** |
| Lasalvia et al., (2021)33 | **\*** | **\*** |  | **\*** | **\*** | **\*** | **\*** | **\*** | **7** |
| Appiani et al., (2021)43 | **\*** |  |  |  | **\*** | **\*** | **\*** |  | **4** |
| Elghazally et al., (2021)38 | **\*** | **\*** |  |  |  **\*** | **\*** | **\*** |  | **5** |
| Bahadirli and Sagaltici, (2021)40 |  | **\*** |  |  | **\*** | **\*** | **\*** | **\*** | **5** |
| Aziz et al., (2021)29 | **\*** |  **\*** |  |  |  | **\*** |  | **\*** | **4** |
| Degraeve et al., (2020)34 | **\*** | **\*** |  | **\*** | **\*** | **\*** | **\*** | **\*** | **7** |
| Osama et al., (2020)41 | **\*** | **\*** |  |  | **\*** | **\*** | **\*** | **\*** | **6** |
| Poelmann et al., (2021)35 | **\*** | **\*** | **\*** | **\*** |  | **\*** | **\*** |  | **6** |

The studies with more than 6 starts (maximum 8) were classified as low risk of bias, studies with 5 to 6 starts as moderate risk of bias, whilst studies with less than 5 starts were deemed as being of high risk of bias.